Oncimmune has released its FY results to May-21. Whilst largely historic, they reflect the strategic progress made with the ImmunoINSIGHTS business in particular, supported by a £9.0m equity raise in March. A number of significant new customers have been won and capacity expansion is underway to satisfy the expected increase in demand from these and a significant pipeline of opportunities, which is accelerating after an unexpectedly quiet pharma services market in Q1. We make no change to our fo ....
02 Nov 2021
Looming inflection as ImmunoINSIGHTS scales
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Looming inflection as ImmunoINSIGHTS scales
Oncimmune Holdings Plc (ONC:LON) | 27.6 -0.4 (-5.2%) | Mkt Cap: 20.5m
- Published:
02 Nov 2021 -
Author:
Chris Glasper -
Pages:
3
Oncimmune has released its FY results to May-21. Whilst largely historic, they reflect the strategic progress made with the ImmunoINSIGHTS business in particular, supported by a £9.0m equity raise in March. A number of significant new customers have been won and capacity expansion is underway to satisfy the expected increase in demand from these and a significant pipeline of opportunities, which is accelerating after an unexpectedly quiet pharma services market in Q1. We make no change to our fo ....